drugset / Trial / NCT04335890

IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma

NCT04335890 ↗

Phase 1 Completed 17 enrolled Hasumi International Research Foundation
NaSingle-groupOpen-labelTreatment

Summary

A Phase I vaccination trial in patients suffering from recently diagnosed metastatic uveal melanoma not cureable with local therapy and needing systemic therapy. IKKb-matured Dendritic Cells loaded with autologous tumor-RNA + RNA coding for defined antigens and driver mutations will be added to a standard therapy chosen by the tumor board (either checkpoint blockade or chemotherapy).

Timeline

Start
2020-09-24
Primary completion
2022-09-20
Completion
2024-11-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject DCIKKb Cell therapy 3e+07 cells Intravenous

Indications